about
Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated ratsApparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinolLigand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive propertiesDesign, synthesis, binding and docking-based 3D-QSAR studies of 2-pyridylbenzimidazoles--a new family of high affinity CB1 cannabinoid ligands.Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.Anandamide capacitates bull spermatozoa through CB1 and TRPV1 activationA putative 'pre-nervous' endocannabinoid system in early echinoderm development.Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus.Detection and Characterization of the Effect of AB-FUBINACA and Its Metabolites in a Rat ModelNovel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).N-acylethanolamines as novel alcohol dehydrogenase 3 substrates.The endocannabinoid system and painChronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoidsCannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neuronsWIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.Endocannabinoids and their implications for epilepsy.Modulation of the endocannabinoid system: therapeutic potential against cocaine dependenceThe role of the endocannabinoid system in the control of energy homeostasis.Endocannabinoid mechanisms of pain modulationEndocannabinoids and the gastrointestinal tract: what are the key questions?Development of novel tail-modified anandamide analogs.Novel adamantyl cannabinoids as CB1 receptor probes.Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.Biosynthesis, degradation and pharmacological importance of the fatty acid amidesAnandamide-induced behavioral disruption through a vanilloid-dependent mechanism in ratsCannabinoid regulation of nitric oxide synthase I (nNOS) in neuronal cellsThe role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model.Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitorsNovel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.Anxiolytic-like properties of the anandamide transport inhibitor AM404.Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions.Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.Potential of Endocannabinoids to Control Bladder Pain.
P2860
Q28271665-8D49ABAE-89AB-4204-A083-BC2625D35992Q28833498-7AF268E0-829C-4612-B735-3ACAE4ECE7FEQ30373403-043292C3-7947-4A36-94CB-A5CEF8653FC9Q30580156-ABB0E69C-F9E9-4788-B067-48877DF23EF4Q30612575-3A2C4438-7CA1-40C9-8F16-98D1D7573243Q30842363-BFB8C252-DEC8-49F1-875B-34398CB53E0DQ33698310-BD35181B-EEF0-464A-9985-618D3D154E8DQ33733994-EBDFE449-DDC2-4E30-886F-00C316FABBAEQ33828435-8E248EA3-CF45-406A-B4C2-D4057B33214CQ33837421-796052A9-CE24-4BF3-B4EC-236C53132852Q34312878-1FF93BB8-2C95-4992-BE97-A57B4DC417CBQ34499961-6124722C-84AE-4D51-BEF0-424DF1175F05Q34500324-DE623F0F-5AAE-4A02-AEC6-9DC6A0DA319EQ34538297-57FE03A4-91DE-4107-802D-F1463557CEBDQ34612917-FA690A97-0ADA-4ED9-A2CA-4E53A482C56FQ34636231-73A73695-41EA-42F7-AA54-29BC3ABC3EB8Q35047139-14D1C1E1-1BE5-47C1-AA02-910E1BE88F79Q35601542-ED31EBEF-80B1-43CF-8FB1-F24B2C96261BQ36214144-62528909-2549-44FA-8376-522D0419ED3BQ36259799-2EC105BA-28B8-4A66-8E6E-53E5E90A938DQ36434442-44B71268-E110-41E9-8ACB-2E216D40325BQ36711160-FDB6B779-FC04-4AAF-BC66-07CE3304B55EQ36927486-0D463EC1-B570-4D73-9847-F5B3F8B228CFQ36956799-7325A28A-27AC-465F-976D-EA27CCBDBD72Q36996148-2B0CCF7D-9FB4-440E-B351-6D9654ECF83EQ36997712-61676CFA-DD7B-458F-B20C-2719029BEFBCQ37155833-2D6F7879-BD54-4072-80AF-5AF7F1B79740Q37224649-BD3DCAB2-3BA5-4619-8666-3AEE0E8A20C9Q37286102-4A759229-A00C-485B-916F-94FCF2EA7E74Q37361714-875695A2-6755-478E-BB48-CB23DDCD5B71Q37668664-9F6CE9B5-E85A-47D0-AED4-56DB7D5A22F6Q37668713-D994EE1D-332B-47E0-A46B-94A069D1A2FEQ41774329-E21619FD-A7D0-4FA5-B7F3-DAA00ED9B066Q46689323-FDE2A120-6A54-4190-84BB-40383353D0D1Q46713327-FBFA1A1E-75DC-417F-8AAE-1CEEE4953FC7Q47593740-AAB9A421-0EBC-4241-A80D-CDF892347F29Q50437270-4713ACEB-0E33-4613-AE84-CE0E036CA0E9Q55002764-36B962AE-928E-4AEB-A26F-8D5206DDE7FE
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cannabinergic ligands.
@ast
Cannabinergic ligands.
@en
Cannabinergic ligands.
@nl
type
label
Cannabinergic ligands.
@ast
Cannabinergic ligands.
@en
Cannabinergic ligands.
@nl
prefLabel
Cannabinergic ligands.
@ast
Cannabinergic ligands.
@en
Cannabinergic ligands.
@nl
P1476
Cannabinergic ligands.
@en
P2093
Ganesh A Thakur
Sonya L Palmer
P356
10.1016/S0009-3084(02)00143-3
P577
2002-12-01T00:00:00Z